ad image

Orphan Drugs

1 / 2
From Market Failures to Lifesaving Innovations: The Evolution of Orphan Drugs
Orphan Drugs

From Market Failures to Lifesaving Innovations: The Evolution of Orphan Drugs

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-25-30-06Mar 02, 2025
In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?
Unmet Needs

In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?

Pharma's Almanac

PAO-06-022--RT-01Jun 24, 2022
Trends Shaping the Dynamic Market for Parenterals
Parenterals

Trends Shaping the Dynamic Market for Parenterals

Marga Viñes

Grifols

PAP-Q3-20-CL-018Sep 29, 2020
Advancing Commercial Manufacturing from Orphan Drugs to Blockbusters
Commercial Manufacturing

Advancing Commercial Manufacturing from Orphan Drugs to Blockbusters

Tyler Ewald

UPM Pharmaceuticals

PAP-Q4-19-CL-032Dec 06, 2019
Innovative Therapies to Treat Rare and Underserved Eye Diseases
Ophthalmology

Innovative Therapies to Treat Rare and Underserved Eye Diseases

Shankar Musunuri, Ph.D.

Ocugen

PAP-Q4-19-CL-025Dec 06, 2019
Customer Engagement and Information Sharing are Essential for Success in Orphan Drug Outsourcing
Orphan Drugs

Customer Engagement and Information Sharing are Essential for Success in Orphan Drug Outsourcing

Marga Viñes

Grifols

PAP-Q3-19-CL-013Oct 29, 2019
Catering to a Growing Demand for Small-Volume Parenteral Manufacturing
Parenteral Manufacturing

Catering to a Growing Demand for Small-Volume Parenteral Manufacturing

Oriol Prat

Grifols

PAO-M04-19-CL-001May 28, 2019
Where Do 
Orphan Drugs 
Go From Here?
Nice Insight Overview

Where Do 
Orphan Drugs 
Go From Here?

Nigel Walker

Nice Insight

PAP-Q2-2019-NI-004May 24, 2019
An Expanding Orphan Drug Market
Orphan Drug Development

An Expanding Orphan Drug Market

Cynthia A. Challener, Ph.D.; Emilie Branch; David Alvaro, Ph.D.

Pharma's Almanac

PAP-Q2-2019-NI-001May 24, 2019
Managing the Risks Associated with Orphan Drug Development and Manufacturing
Orphan Drug Development

Managing the Risks Associated with Orphan Drug Development and Manufacturing

Cynthia A. Challener, Ph.D.; Emilie Branch; David Alvaro, Ph.D.

Pharma's Almanac

PAP-Q2-2019-NI-002May 24, 2019
Navigating the Road to Successful Orphan Drug Commercialization and Launch
Orphan Drug Development

Navigating the Road to Successful Orphan Drug Commercialization and Launch

Cynthia A. Challener, Ph.D.; Emilie Branch; David Alvaro, Ph.D.

Pharma's Almanac

PAP-Q2-2019-NI-003May 24, 2019
Facilitating Complex Clinical Trials For Rare Diseases
Clinical Trial Logistics

Facilitating Complex Clinical Trials For Rare Diseases

Ariette van Strien

Marken

PAP-Q1-2019-CL-003Mar 12, 2019
Cholangiocarcinoma Drug Receives Orphan Drug Designation from FDA
Orphan Drug

Cholangiocarcinoma Drug Receives Orphan Drug Designation from FDA

Cynthia A. Challener, Ph.D.

Pharma's Almanac

PAO-M03-19-NI-003Mar 05, 2019
BioInvent
FDA

BioInvent Receives FDA Orphan Designation for BI-1206 for Mantle Cell Lymphoma

BioInvent

PR-M01-19-NI-088Jan 30, 2019
Arrowhead Pharmaceuticals
Orphan Drug

Arrowhead Receives Positive EMA Opinion on Orphan Designation for ARO-AAT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency

Arrowhead Pharmaceuticals

PR-M06-18-NI-097Jun 29, 2018
Samus Therapeutics
Orphan Drug

Samus Therapeutics Announces PU-H71 Granted Orphan Drug Designation and First Patient Dosed in Phase 1b Study in Myelofibrosis

Samus Therapeutics

PR-M06-18-NI-050Jun 14, 2018
Scholar Rock
FDA

Scholar Rock Granted Orphan Drug Designation by the FDA for SRK-015 for the Treatment of Patients with Spinal Muscular Atrophy

Scholar Rock

PR-M04-18-NI-003-4472Apr 02, 2018
Kazia Therapeutics Limited
Orphan Drug

Kazia Receives FDA Orphan Designation for GDC-0084

Kazia Therapeutics Limited

PR-M02-18-NI-107Feb 28, 2018
Merck & Co.
Orphan Drug

Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Neurofibromatosis Type 1

Merck & Co.

PR-M02-18-NI-76Feb 21, 2018
MEI Pharma, Inc.
Orphan Drug Designation

Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of Acute Myeloid Leukemia (AML)

MEI Pharma, Inc.

PR-M01-18-NI-045Jan 16, 2018
1 / 2